- Continued strong focus on cost control with improvement in first half
operating loss and cash burn over 2010 
- Improving 2011 guidance as result of DKK 25 million reduction in operating
expenses 
- Announced HuMax-CD74™ antibody-drug conjugate program with Seattle Genetics
- Decisive move to minimize future spending by winding down the zalutumumab
program 

In order to read Genmab's Interim Report for the 6 months ended June 30, 2011
please see the attached file. 

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communication 
T: +45 33 44 77 20
M: +45 25 12 62 60
E: r.gravesen@genmab.com
www.genmab.com

Company Announcement no. 24
CVR no. 2102 3884

Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark